All Drug Development articles
-
NewsHuman antimicrobial peptide dermcidin shows antiviral activity against influenza
Researchers at Fisabio Foundation have discovered that dermcidin, an antimicrobial peptide naturally present in human sweat, exhibits antiviral activity against influenza by binding to viral haemagglutinin and preventing cell fusion, opening new possibilities for innate immunity-based therapeutics.
-
NewsMirrored molecules target disordered proteins in Alzheimer’s disease
Researchers at Kobe University have developed a novel approach to Alzheimer’s disease treatment by engineering right-handed amino acid chains that bind to amyloid-beta proteins. The method, inspired by materials science principles of chirality, demonstrated effective inhibition of toxic protein aggregation in mouse brain cell cultures, maintaining cell viability where amyloid-beta alone reduced it by 50 percent.
-
ReportCRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
-
ArticleAnticipating adaptation: understanding and overcoming cancer drug resistance
Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.
-
ArticleWhy NMDA receptor modulation remains central to next-generation depression therapies
A key player in brain communication and mood regulation, the pharmaceutical industry views the NMDAR as the central pillar for next-generation therapies for depression. Dirk Beher from FundaMental Pharma reveals new strategies for targeting this important receptor.
-
NewsNew drug delivery system boosts paclitaxel cancer treatment
Researchers at Osaka Metropolitan University have developed a novel drug delivery system that improves the solubility of the anticancer drug paclitaxel.
-
NewsScientists develop cream that triggers skin’s anti-cancer defence
A topical cream that activates the skin’s immune defences has been shown to suppress tumour growth in early models of cutaneous squamous cell carcinoma.
-
NewsDeep-sea compound yaku’amide B shows new cancer-fighting mechanism
Japanese researchers have discovered how yaku’amide B, a rare compound from deep-sea sponges, targets aggressive cancer cells.
-
NewsLab-made lncRNA could lead to new anti-inflammatory drugs
Scientists at the University of Toronto have created long noncoding RNA outside living cells for the first time, a breakthrough that has already produced experimental anti-inflammatory molecules.
-
ArticleNavigating IND delays: strategic options for early-phase biotech development
As IND timelines lengthen, early-stage biotechs face growing uncertainty in early clinical planning. This article explores how sponsors are increasingly diversifying their development strategies and why New Zealand represents an attractive option.
-
NewsNew target found for glaucoma treatment
Scientists have discovered that specialised immune cells in the eye help keep its drainage system clear and regulate pressure, which could inform new treatments for glaucoma.
-
ArticleWorld ADC 2026: where antibody-drug conjugates are heading
At World ADC London 2026, experts highlighted how advances in payload design, targeting strategies and AI-driven discovery are changing antibody–drug conjugate development.
-
NewsNew AI tool could accelerate drug discovery and cut lab costs
Scientists have developed a machine learning system that can predict how complex chemical reactions will produce the correct molecular form for medicines.
-
NewsARK1 identified as target for future malaria drugs
Scientists have identified Aurora-related kinase 1 (ARK1) as a vital protein in malaria parasite development, a breakthrough that could enable future drugs designed to block transmission.
-
NewsCircular RNA drives 50-fold boost in eye gene therapy
New in vivo data show a circular RNA platform can deliver up to a 50-fold increase in gene expression in the eye compared with conventional mRNA-based AAV approaches.
-
NewsBispecific EGFR/EphA2-targeting ADC shows promise in colorectal cancer
Promatix Biosciences Ltd has announced positive preclinical data for its first-in-class bispecific antibody–drug conjugate, PBS293-MMAE, demonstrating enhanced tumour selectivity, improved suppression and reduced toxicity in colorectal cancer models.
-
NewsTargeting senescent cells may reduce postpartum breast cancer risk
A study from the Institut Pasteur reveals how cellular senescence during mammary gland involution after pregnancy may both aid tissue repair and promote postpartum breast cancer.
-
News$3.2m project targets aggressive MDM2 in breast cancer
A University of Houston scientist has joined a $3.2 million research collaboration to develop a new drug targeting one of the key drivers of triple-negative breast cancer.
-
NewsAMD3100 drug could boost immunotherapy in rare liver cancer
A rare liver cancer that primarily affects young people may soon have a new treatment option, after researchers found that an existing FDA-approved drug could enable immunotherapy to work effectively against tumours.
-
ArticleEngineering the next generation of T-cell engagers
T-cell engagers are a branch of immunotherapy that has undergone considerable change since their clinical inception. Andrew J Souers, VP, Oncology Discovery Research at AbbVie, elucidates the current understanding of their biology and expanding focus areas of application.